EVERYTHING
A new class of medicines, gene therapies, is transforming health care by offering potential cures for chronic diseases like sickle cell anemia with just one treatment. Yet, the financial barrier remains immense; these interventions often carry a price tag exceeding $2 million per patient. This cost reflects their nature as curative treatments that can prevent years of hospitalizations and lost productivity, concentrating decades of value into a single event. However, Statnews reports that many eligible patients are unable to receive these life-saving therapies because the current US health care system lacks the necessary mechanisms to absorb such large upfront costs.
The Challenge of Upfront Investment
The core problem is structural: the health system is designed around annual budgets and struggles to finance treatments that deliver value over decades. In response, under the Biden administration, the Centers for Medicare and Medicaid Services (CMS) launched the Cell and Gene Therapy Access Model. This voluntary program aims to help state Medicaid agencies improve access through multistate purchasing and outcomes-based payment arrangements.
While this model reflects a growing recognition of the problem, its effectiveness is constrained by underlying financial realities. Early analyses indicate that these models may improve marginal access but do not fundamentally alter how costs are financed. States remain bound by budget cycles, creating uncertainty for manufacturers attempting to scale treatment. The limitations include:
- Insurers and state Medicaid programs operate on rigid annual budgets.
- A $2 million upfront cost is difficult to absorb, even if the therapy provides long-term health benefits.
- Coverage remains limited, and approvals are often slow outside of the rarest conditions.
Beyond Price: The Delivery Infrastructure
Some policymakers suggest that prices will naturally fall as these therapies scale up in production. However, this assumption does not align with how gene therapies function. Unlike mass-produced pills, these treatments are closer to organ transplants, requiring highly specialized centers and extensive clinical capacity. Therefore, simply lowering the price alone cannot resolve the access constraints; it merely shifts the bottleneck elsewhere.
Expanding treatment volume requires a corresponding expansion in patient identification, clinical delivery infrastructure, and trained teams—none of which scale automatically with a lower price point. This dynamic explains current market behavior: companies often choose to treat fewer patients at higher prices because expanding access necessitates building out the entire delivery system, not just adjusting the cost structure.
Ultimately, the absence of a robust mechanism to finance large, upfront investments in curative care while aligning incentives among payers, providers, and manufacturers remains the defining obstacle to widespread patient access. The scientific capability is present; the financial infrastructure required for its delivery is missing.